Moffitt Cancer Center begins Phase I clinical trial of new immunotherapy

April 10, 2014

Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person's own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.

"This clinical trial is to assess ID-G305 and its ability to activate the immune system in patients with advanced stage melanoma, sarcoma, lung, ovarian, or ," said Amit Mahipal, M.D., M.P.H., medical director of Moffitt's Clinical Research Unit. "Our first patient in this trial is a metastatic sarcoma patient who has undergone two previous surgeries and one chemotherapy regimen."

ID-G305 is a cancer vaccine that is made up of two parts, a protein called NY-ESO-1 that is found in many different types of cancer, and an agent called GLAASTM developed by Immune Design. GLAASTM activates a type of cell called a dendritic cell that normally searches for pathogens in the body and helps the immune system fight against the infection. Following vaccination, the GLAASTM-activated dendritic cells recognize NY-ESO-1 as a foreign protein and cause the body to produce an . Since NY-ESO-1 is found on tumors, the begins targeting the cancer cells.

"Only 10 to 15 percent of all tumors have NY-ESO-1 protein expression. Therefore, patients for this trial need to be to be screened for NY-ESO-1. The vaccine will likely not work for patients with tumors that do not have detectable levels of the protein," said Mahipal.

Each component of ID-G305 has been used previously as a single-agent in and was well tolerated by patients. This trial will determine the ideal concentration of each agent to use in combination. Common side effects expected include pain, redness, and inflammation at the site of injection.

This is an exciting time for the development of new immunotherapies to fight cancer. Several immunotherapy agents have recently been approved by the Food and Drug Administration, including interleukin-2 for melanoma and , Provenge for prostate cancer and ipilimumab for melanoma.

"New immune therapies are emerging," explained Mahipal. "If we can have actually work it would be great for the patient and reduce side effects associated with traditional chemotherapies."

Explore further: Recurrent ovarian cancers respond to cancer vaccine after 'reprogramming' with decitabine

Related Stories

Recurrent ovarian cancers respond to cancer vaccine after 'reprogramming' with decitabine

January 3, 2014
Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide ...

Experimental drug shows early promise for some cases of advanced melanoma

April 8, 2014
(HealthDay)—An experimental cancer drug that activates the immune system has shown early promise for advanced cases of melanoma skin cancer, researchers report.

Genetic testing beneficial in melanoma treatment

April 4, 2014
(Medical Xpress)—Genetic screening of cancer can help doctors customize treatments so that patients with melanoma have the best chance of beating it, according to the results of a clinical trial by researchers at the University ...

Pox vaccines extend survival for patients with melanoma, ovarian cancer

March 26, 2012
An immunotherapy regimen incorporating poxviruses and targeting a particular tumor antigen, NY-ESO-1, has shown promise in treating two types of cancers. Kunle Odunsi, MD, PhD, Chair of the Department of Gynecologic Oncology ...

Study finds promising therapeutic target for hard-to-treat brain tumor

August 27, 2013
Johns Hopkins researchers say they have found a specific protein in nearly 100 percent of high-grade meningiomas—the most common form of brain tumor—suggesting a new target for therapies for a cancer that does not respond ...

Novel cancer vaccine holds promise against ovarian cancer, mesothelioma

March 5, 2014
A novel approach to cancer immunotherapy – strategies designed to induce the immune system to attack cancer cells – may provide a new and cost-effective weapon against some of the most deadly tumors, including ovarian ...

Recommended for you

Study sheds light on how body may detect early signs of cancer

July 26, 2017
Fresh insights into how cells detect damage to their DNA - a hallmark of cancer - could help explain how the body keeps disease in check.

How genetically engineered viruses develop into effective vaccines

July 26, 2017
Lentiviral vectors are virus particles that can be used as a vaccine to stimulate the immune system to fight against specific pathogens. The vectors are derived from HIV, rendered non-pathogenic, and then engineered to carry ...

Does your child really have a food allergy?

July 24, 2017
(HealthDay)—Many people misunderstand what food allergies are, and even doctors can be confused about how to best diagnose them, suggests a new report from the American Academy of Pediatrics.

Genetic immune deficiency could hold key to severe childhood infections

July 18, 2017
A gene mutation making young children extremely vulnerable to common viruses may represent a new type of immunodeficiency, according to a University of Queensland researcher.

What are the best ways to diagnose and manage asthma?

July 18, 2017
What are the best ways to diagnose and manage asthma in adults? This can be tricky because asthma can stem from several causes and treatment often depends on what is triggering the asthma.

Large multi-ethnic study identifies many new genetic markers for lupus

July 17, 2017
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.